SIRT6 is a DNA double-strand break sensor.


Journal

eLife
ISSN: 2050-084X
Titre abrégé: Elife
Pays: England
ID NLM: 101579614

Informations de publication

Date de publication:
29 01 2020
Historique:
received: 04 09 2019
accepted: 23 01 2020
pubmed: 30 1 2020
medline: 10 4 2021
entrez: 30 1 2020
Statut: epublish

Résumé

DNA double-strand breaks (DSB) are the most deleterious type of DNA damage. In this work, we show that SIRT6 directly recognizes DNA damage through a tunnel-like structure that has high affinity for DSB. SIRT6 relocates to sites of damage independently of signaling and known sensors. It activates downstream signaling for DSB repair by triggering ATM recruitment, H2AX phosphorylation and the recruitment of proteins of the homologous recombination and non-homologous end joining pathways. Our findings indicate that SIRT6 plays a previously uncharacterized role as a DNA damage sensor, a critical factor in initiating the DNA damage response (DDR). Moreover, other Sirtuins share some DSB-binding capacity and DDR activation. SIRT6 activates the DDR before the repair pathway is chosen, and prevents genomic instability. Our findings place SIRT6 as a sensor of DSB, and pave the road to dissecting the contributions of distinct DSB sensors in downstream signaling. DNA is a double-stranded molecule in which the two strands run in opposite directions, like the lanes on a two-lane road. Also like a road, DNA can be damaged by use and adverse conditions. Double-strand breaks – where both strands of DNA snap at once – are the most dangerous type of DNA damage, so cells have systems in place to rapidly detect and repair this kind of damage. There are three confirmed sensors for double-strand break in human cells. A fourth protein, known as SIRT6, arrives within five seconds of DNA damage, and was known to make the DNA more accessible so that it can be repaired. However, it was unclear whether SIRT6 could detect the double-strand break itself, or whether it was recruited to the damage by another double-strand break sensor. To address this issue, Onn et al. blocked the three other sensors in human cells and watched the response to DNA damage. Even when all the other sensors were inactive, SIRT6 still arrived at damaged DNA and activated the DNA damage response. To find out how SIRT6 sensed DNA damage, Onn et al. examined how purified SIRT6 interacts with different kinds of DNA. This revealed that SIRT6 sticks to broken DNA ends, especially if the end of one strand slightly overhangs the other – a common feature of double-strand breaks. A closer look at the structure of the SIRT6 protein revealed that it contains a narrow tube, which fits over the end of one broken DNA strand. When both strands break at once, two SIRT6 molecules cap the broken ends, joining together to form a pair. This pair not only protects the open ends of the DNA from further damage, it also sends signals to initiating repairs. In this way, SIRT6 could be thought of acting like a paramedic who arrives first on the scene of an accident and works to treat the injured while waiting for more specialized help to arrive. Understanding the SIRT6 sensor could improve knowledge about how cells repair their DNA. SIRT6 arrives before the cell chooses how to fix its broken DNA, so studying it further could reveal how that critical decision happens. This is important for medical research because DNA damage builds up in age-related diseases like cancer and neurodegeneration. In the long term, these findings can help us develop new treatments that target different types of DNA damage sensors.

Autres résumés

Type: plain-language-summary (eng)
DNA is a double-stranded molecule in which the two strands run in opposite directions, like the lanes on a two-lane road. Also like a road, DNA can be damaged by use and adverse conditions. Double-strand breaks – where both strands of DNA snap at once – are the most dangerous type of DNA damage, so cells have systems in place to rapidly detect and repair this kind of damage. There are three confirmed sensors for double-strand break in human cells. A fourth protein, known as SIRT6, arrives within five seconds of DNA damage, and was known to make the DNA more accessible so that it can be repaired. However, it was unclear whether SIRT6 could detect the double-strand break itself, or whether it was recruited to the damage by another double-strand break sensor. To address this issue, Onn et al. blocked the three other sensors in human cells and watched the response to DNA damage. Even when all the other sensors were inactive, SIRT6 still arrived at damaged DNA and activated the DNA damage response. To find out how SIRT6 sensed DNA damage, Onn et al. examined how purified SIRT6 interacts with different kinds of DNA. This revealed that SIRT6 sticks to broken DNA ends, especially if the end of one strand slightly overhangs the other – a common feature of double-strand breaks. A closer look at the structure of the SIRT6 protein revealed that it contains a narrow tube, which fits over the end of one broken DNA strand. When both strands break at once, two SIRT6 molecules cap the broken ends, joining together to form a pair. This pair not only protects the open ends of the DNA from further damage, it also sends signals to initiating repairs. In this way, SIRT6 could be thought of acting like a paramedic who arrives first on the scene of an accident and works to treat the injured while waiting for more specialized help to arrive. Understanding the SIRT6 sensor could improve knowledge about how cells repair their DNA. SIRT6 arrives before the cell chooses how to fix its broken DNA, so studying it further could reveal how that critical decision happens. This is important for medical research because DNA damage builds up in age-related diseases like cancer and neurodegeneration. In the long term, these findings can help us develop new treatments that target different types of DNA damage sensors.

Identifiants

pubmed: 31995034
doi: 10.7554/eLife.51636
pii: 51636
pmc: PMC7051178
doi:
pii:

Substances chimiques

SIRT6 protein, human EC 3.5.1.-
Sirtuins EC 3.5.1.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Israel Science Foundation
ID : 188/17
Organisme : Ben Gurion University
ID : High-tech, Bio-tech and Chemo-tech scholarship

Informations de copyright

© 2020, Onn et al.

Déclaration de conflit d'intérêts

LO, MP, SI, GC, DS, SK, IS, ZS, ME, FE, BA, DT No competing interests declared

Références

Mol Cell. 2017 Sep 7;67(5):891-898.e4
pubmed: 28867292
Cell Rep. 2014 Jul 10;8(1):177-89
pubmed: 24953651
Nature. 2009 Oct 22;461(7267):1071-8
pubmed: 19847258
J Biol Chem. 2013 Oct 25;288(43):31350-6
pubmed: 24052263
Proc Natl Acad Sci U S A. 2008 Aug 12;105(32):11200-5
pubmed: 18678890
Mol Cell. 2009 Sep 24;35(6):741-53
pubmed: 19782025
Cell. 2010 Jan 22;140(2):280-93
pubmed: 20141841
Trends Biochem Sci. 2014 Feb;39(2):72-81
pubmed: 24438746
Neuron. 2014 Jul 16;83(2):266-282
pubmed: 25033177
DNA Repair (Amst). 2013 Aug;12(8):620-36
pubmed: 23684800
J Biol Chem. 2005 Jun 3;280(22):21313-20
pubmed: 15795229
Cell. 2010 Jun 11;141(6):970-81
pubmed: 20550933
Annu Rev Biochem. 2008;77:229-57
pubmed: 18275380
Nat Struct Mol Biol. 2013 Mar;20(3):317-25
pubmed: 23377543
Cell Rep. 2017 Mar 21;18(12):2880-2892
pubmed: 28329681
J Biol Chem. 2008 Jan 4;283(1):1-5
pubmed: 17999957
Dis Model Mech. 2014 Sep;7(9):1023-32
pubmed: 25085992
Nucleic Acids Res. 2013 Oct;41(18):8537-45
pubmed: 23892288
Proc Natl Acad Sci U S A. 2010 Aug 24;107(34):15033-8
pubmed: 20696935
Nat Struct Mol Biol. 2009 Aug;16(8):814-8
pubmed: 19633669
EMBO J. 2014 Oct 16;33(20):2422-35
pubmed: 25107472
Mol Cell. 2013 Mar 7;49(5):872-83
pubmed: 23333306
Exp Cell Res. 2014 Nov 15;329(1):154-61
pubmed: 25218947
PLoS One. 2015 May 15;10(5):e0127321
pubmed: 25978375
Biophys J. 1999 Jun;76(6):2879-86
pubmed: 10354416
Mech Ageing Dev. 2010 Mar;131(3):185-92
pubmed: 20117128
Nature. 2003 Jan 30;421(6922):486-8
pubmed: 12556872
Cell Rep. 2016 Feb 16;14(6):1435-1447
pubmed: 26854234
Cell Rep. 2017 Mar 28;18(13):3052-3062
pubmed: 28355558
Cell. 2019 Apr 18;177(3):622-638.e22
pubmed: 31002797
Environ Mol Mutagen. 2015 Jan;56(1):1-21
pubmed: 25111769
J Cell Biol. 2014 Dec 22;207(6):717-33
pubmed: 25533843
Science. 2011 Jun 17;332(6036):1443-6
pubmed: 21680843
Neural Regen Res. 2017 Sep;12(9):1441-1442
pubmed: 29089988
Curr Opin Cell Biol. 2007 Apr;19(2):238-45
pubmed: 17303408
Cancers (Basel). 2018 Oct 30;10(11):
pubmed: 30380732
J Biol Chem. 2008 Jan 11;283(2):1197-208
pubmed: 18025084
N Engl J Med. 2009 Oct 8;361(15):1475-85
pubmed: 19812404
Cell. 2008 Oct 3;135(1):97-109
pubmed: 18854158
Sci Rep. 2018 Feb 23;8(1):3538
pubmed: 29476161
Science. 2010 Sep 10;329(5997):1348-53
pubmed: 20829486
Nucleus. 2017 Mar 4;8(2):107-115
pubmed: 28406750
Angew Chem Int Ed Engl. 2017 Jan 19;56(4):1007-1011
pubmed: 27990725
EMBO J. 2016 Jul 15;35(14):1483-5
pubmed: 27302089
Exp Mol Med. 2007 Feb 28;39(1):8-13
pubmed: 17334224
Aging (Albany NY). 2009 Jan 15;1(1):109-21
pubmed: 20157594
Mech Ageing Dev. 2017 Jul;165(Pt A):33-46
pubmed: 27614000
Nature. 2013 Apr 4;496(7443):110-3
pubmed: 23552949
Nat Commun. 2016 Jul 20;7:12235
pubmed: 27436229
Mol Cell. 2013 Aug 22;51(4):454-68
pubmed: 23911928
Mol Cell. 2010 Oct 22;40(2):179-204
pubmed: 20965415
Trends Endocrinol Metab. 2017 Mar;28(3):168-185
pubmed: 27836583
Cell Rep. 2015 Oct 20;13(3):479-488
pubmed: 26456828
J Biol Chem. 2002 Mar 22;277(12):9741-8
pubmed: 11796732
Science. 2008 Jun 13;320(5882):1507-10
pubmed: 18483401
Mol Cell Biol. 2014 Apr;34(8):1380-8
pubmed: 24469398
J Neurochem. 2018 Jan;144(2):128-138
pubmed: 29049850
Semin Cancer Biol. 2016 Jun;37-38:26-35
pubmed: 26773346
Genes Dev. 2018 Mar 1;32(5-6):373-388
pubmed: 29555651
IUCrJ. 2018 May 30;5(Pt 4):402-409
pubmed: 30002841
Nucleic Acids Res. 2018 Apr 20;46(7):3446-3457
pubmed: 29447383
Nucleic Acids Res. 2014 May;42(9):5616-32
pubmed: 24598253
Cell. 2010 Apr 16;141(2):243-54
pubmed: 20362325

Auteurs

Lior Onn (L)

Department of Life Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.
The Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Miguel Portillo (M)

Department of Life Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.
The Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Stefan Ilic (S)

Department of Chemistry, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Gal Cleitman (G)

Department of Life Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.
The Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Daniel Stein (D)

Department of Life Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.
The Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Shai Kaluski (S)

Department of Life Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.
The Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Ido Shirat (I)

Department of Life Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.
The Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Zeev Slobodnik (Z)

Department of Life Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.
The Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Monica Einav (M)

Department of Life Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.
The Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Fabian Erdel (F)

Division of Chromatin Networks, German Cancer Research Center (DKFZ), BioQuant, Heidelberg, Germany.
Centre de Biologie Intégrative, CNRS UPS, Toulouse, France.

Barak Akabayov (B)

Department of Chemistry, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Debra Toiber (D)

Department of Life Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.
The Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH